Clinical trial · Interventional
Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients
A Phase IB, Open-Label, Safety Study of the Combination of Sunitinib and Radiation for the Treatment of Patients With Cancer
NCT00437372CI-TRIAL-00089224completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is using the combination of radiation and antiangiogenic agents (agents that destroy existing blood vessels) seems to be an approach to tumor cure.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
| Nervous System Neoplasms | Nervous System Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Pelvic Cancer | Malignant Pelvic Neoplasm | ALIAS | 0.90 |
| Thoracic Neoplasms | Thoracic Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| External Beam Radiation Therapy | Radiation | — | UNRESOLVED |
| Sunitinib | Drug | Sunitinib | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Sunitinib plus Radiation
- description
- Sunitinib plus Radiation
- interventionNames
- Drug: Sunitinib
- Radiation: External Beam Radiation Therapy
Primary outcomes (1)
- measure
- To evaluate the safety and toxicity profile of sunitinib when used with concurrent radiation therapy
- timeFrame
- 2 years
- description
- The purpose of this study is to determine the safety of the combination of the antiangiogenic, sunitinib, when combined with external beam radiotherapy.
Secondary outcomes (1)
- measure
- To measure urine VEGF
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Minimum 2 week course of radiation therapy * Solid tumors of the central nervous system, head and neck, thorax, and pelvis Exclusion Criteria: * Major surgery or radiation therapy within 4 weeks starting study treatment * Grade 3 hemorrhage within 4 weeks
References
Publications (0)
Data not yet available
No reference posted for this study.